Registry study of fluzoparib for ovarian, tube, or peritoneal cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This is an observational (non-interventional) study that tracks how fluzoparib is used to treat ovarian, fallopian tube, or primary peritoneal cancer in real-world care. It may help doctors better understand how well the treatment works and what side effects patients experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign an informed consent form to join the study
- You are 18 years or older
- You have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer confirmed by lab testing
- Your treating doctor believes you can receive fluzoparib by itself or with other treatments
- If you could become pregnant, you will use reliable birth control during the study and for 90 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
This trial tests a combination of two oral medications—fluzoparib (a PARP inhibitor) and famitinib (a TKI)—as maintenance therapy to keep advanced ovarian cancer from coming back after successful first-line chemotherapy. It is for women whose cancer responded well to initial platinum-based treatment.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests two drugs (fluzoparib with famitinib or SHR-1701) given before surgery to shrink advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if these treatments can make tumors small enough for complete removal or improve the surgery outcome.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.